Verrica Pharmaceuticals Inc. (1NE0)

Overview

Verrica Pharmaceuticals Inc. is an innovative clinical-stage dermatology therapeutics company based in West Chester, Pennsylvania, focusing on the development of novel medications for various skin diseases. Founded in 2013, the company actively works on creating effective therapeutic solutions, emphasizing diseases that currently lack satisfactory treatments. A significant part of Verrica's mission involves targeting challenging dermatological conditions through rigorous clinical trials and strategic collaborations. To this end, it has entered into meaningful partnerships, including with Torii Pharmaceutical Co., Ltd., for the advancement and commercialization of products in Japan, and with Lytix Biopharma AS for the development of dermatological oncology indications. These collaborative efforts are geared toward leveraging Verrica's innovative product pipeline to meet the unmet needs of patients with dermatological conditions globally.

Products and Services

• YCANTH (VP-102)

  This leading product candidate is currently in a phase III clinical trial targeting the treatment of common warts. Its application has also been extended to external genital warts, for which it has completed phase II clinical trials. YCANTH showcases Verrica's dedication to addressing prevalent yet often overlooked dermatological issues with innovative, clinically tested solutions. Additionally, it is approved for treating molluscum contagiosum, highlighting its versatility and potential in dermatology.

• VP-315

  VP-315 is an oncolytic peptide-based injectable therapy in phase II clinical trial aimed at treating dermatology oncological conditions such as basal cell carcinoma. This product highlights Verrica's venture into dermatological oncology, demonstrating the company's broader commitment to combatting skin-related cancers through pioneering therapeutic approaches. The development and commercialization rights for VP-315 have been licensed in collaboration with Lytix Biopharma AS, focusing on significant dermatological oncology indications including non-metastatic melanoma and non-metastatic merkel cell carcinoma.

• VP-103

  VP-103, a cantharidin-based product candidate, is another testament to Verrica's innovative approach to dermatology. It is currently undergoing phase II clinical trial for the treatment of plantar warts. This development underscores the company's dedication to expanding its product pipeline to include treatments for a broader range of dermatological conditions, providing hope for patients suffering from these often painful and persistent skin issues.